Literature DB >> 26888628

Development of additional pituitary hormone deficiencies in pediatric patients originally diagnosed with isolated growth hormone deficiency due to organic causes.

Christopher J Child1, Werner F Blum2, Cheri Deal3, Alan G Zimmermann4, Charmian A Quigley5, Stenvert L S Drop6, Gordon B Cutler7, Ron G Rosenfeld8.   

Abstract

OBJECTIVE: To determine characteristics of children initially diagnosed with isolated growth hormone deficiency (IGHD) of organic aetiology, who later developed multiple pituitary hormone deficiencies (MPHD).
DESIGN: Data were analysed for 716 growth hormone-treated children with organic IGHD, who were growth hormone-naïve at baseline in the multinational, observational Genetics and Neuroendocrinology of Short Stature International Study.
METHODS: Development of MPHD was ascertained from investigator-provided diagnoses, adverse events and concomitant medications. Analyses were performed for all patients and separately for those who developed MPHD within 4.5 years or had >3.5 years follow-up and continued to have IGHD (4-year cohort).
RESULTS: MPHD developed in 71/716 (9.9%) children overall, and in 60/290 (20.7%) in the 4-year cohort. The most frequent additional deficiencies were thyroid-stimulating hormone (47 patients) and gonadotropins (23 patients). Compared with those who remained with IGHD, children who developed MPHD had more severe GHD at study entry, significantly lower baseline insulin-like growth factor1, peak stimulated growth hormone, and more frequent diagnosis of intracranial tumour or mutation of gene(s) controlling hypothalamic-pituitary development and/or function. Multivariate logistic regression analyses identified female gender, longer follow-up, higher baseline age and lower peak stimulated growth hormone as predictors of MPHD development.
CONCLUSIONS: MPHD is more likely to develop in patients with severe organic IGHD, especially those with history of intracranial tumour or mutation of gene(s) controlling hypothalamic-pituitary development and/or function. Older baseline age, female gender and longer follow-up duration were also associated with higher incidence of MPHD. Long-term monitoring of pituitary function is recommended, irrespective of the aetiology of GHD.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26888628     DOI: 10.1530/EJE-15-1203

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement.

Authors:  S Cannavò; M Cappa; D Ferone; A M Isidori; S Loche; M Salerno; M Maghnie
Journal:  J Endocrinol Invest       Date:  2022-08-12       Impact factor: 5.467

2.  Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.

Authors:  Manuela Cerbone; Harshini Katugampola; Helen L Simpson; Mehul T Dattani
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

3.  Declining free thyroxine levels over time in irradiated childhood brain tumor survivors.

Authors:  Laura van Iersel; Sarah C Clement; Antoinette Y N Schouten-van Meeteren; Annemieke M Boot; Hedi L Claahsen-van der Grinten; Bernd Granzen; K Sen Han; Geert O Janssens; Erna M Michiels; A S Paul van Trotsenburg; W Peter Vandertop; Dannis G van Vuurden; Hubert N Caron; Leontien C M Kremer; Hanneke M van Santen
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

4.  Limited Utility of Biochemical Screening for Pituitary Deficiencies and Adverse Effects in Idiopathic GH Deficiency.

Authors:  Stephen Zborovski; Mark R Palmert; Jennifer Harrington
Journal:  J Endocr Soc       Date:  2019-03-28

5.  Growth Responses During 3 Years of Growth Hormone Treatment in Children and Adolescents With Growth Hormone Deficiency: Comparison Between Idiopathic, Organic and Isolated Growth Hormone Deficiency, and Multiple Pituitary Hormone Deficiency.

Authors:  Han Hyuk Lim; Yoo Mi Kim; Gyung Min Lee; Jaehong Yu; Heon-Seok Han; Jeesuk Yu
Journal:  J Korean Med Sci       Date:  2022-03-21       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.